Summary
314.52 2.05(0.66%)05/20/2024
AMGEN Inc. (AMGN)
AMGEN Inc. (AMGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.27 | 9.62 | 11.55 | 1.50 | 11.64 | 31.27 | 99.69 | 120,478.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 300.30 | |
| Open | 301.75 | |
| High | 302.91 | |
| Low | 298.51 | |
| Volume | 2,452,088 | |
| Change | 0.82 | |
| Change % | 0.27 | |
| Avg Volume (20 Days) | 3,097,401 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 211.71 - 329.72 | |
| Price vs 52 Week High | -8.92% | |
| Price vs 52 Week Low | 41.84% | |
| Range | -0.48 | |
| Gap Up/Down | -10.98 | |
Fundamentals | ||
| Market Capitalization (Mln) | 168,730 | |
| EBIDTA | 11,800,999,936 | |
| PE Ratio | 44.2439 | |
| PEG Ratio | 2.3869 | |
| WallStreet Target Price | 316.41 | |
| Book Value | 9.3620 | |
| Earnings Per Share | 7.0100 | |
| EPS Estimate Current Quarter | 3.8700 | |
| EPS Estimate Next Quarter | 4.9800 | |
| EPS Estimate Current Year | 19.4500 | |
| EPS Estimate Next Year | 20.4100 | |
| Diluted EPS (TTM) | 7.0100 | |
| Revenues | ||
| Profit Marging | 0.1274 | |
| Operating Marging (TTM) | 0.1333 | |
| Return on asset (TTM) | 0.0498 | |
| Return on equity (TTM) | 0.7257 | |
| Revenue TTM | 29,532,000,256 | |
| Revenue per share TTM | 55.1480 | |
| Quarterly Revenue Growth (YOY) | 0.2200 | |
| Quarterly Earnings Growth (YOY) | -0.5240 | |
| Gross Profit (TTM) | 19,917,000,000 | |
| Dividends | ||
| Dividend Share | 8.6400 | |
| Dividend Yield | 0.0290 | |
| Valuations | ||
| Trailing PE | 44.2439 | |
| Forward PE | 13.7741 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 22.9890 | |
| Revenue Enterprise Value | 6.9860 | |
| EBITDA Enterprise Value | 13.3056 | |
| Shares | ||
| Shares Outstanding | 536,435,008 | |
| Shares Float | 534,841,481 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.25 | |
| Institutions (%) | 81.17 | |
05/20 21:04 EST - seekingalpha.com
Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
Amgen, Inc. (NASDAQ:AMGN ) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations James Bradner - Executive Vice President, Research and Development Jean-Charles Soria - Senior Vice President, Global Development Oncology Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities Primal Kaur - Vice President, Global Development, Inflammation Conference Call Participants Mohit Bansal - Wells Fargo Matt Phipps - William Blair Carter Gould - Barclays Michael Yee - Jefferies Matthew Dellatorre - Goldman Sachs Evan Seigerman - BMO Capital Markets Geoff Meacham - Bank of America James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Gary Nachman - Raymond James Operator My name is Julianne and I'll be your conference facilitator today for Amgen's Conference Call Following The American Thoracic Society 2024 International Conference and the Approval of IMDELLTRA. All lines have been placed on mute to prevent any background noise.
Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
Amgen, Inc. (NASDAQ:AMGN ) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations James Bradner - Executive Vice President, Research and Development Jean-Charles Soria - Senior Vice President, Global Development Oncology Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities Primal Kaur - Vice President, Global Development, Inflammation Conference Call Participants Mohit Bansal - Wells Fargo Matt Phipps - William Blair Carter Gould - Barclays Michael Yee - Jefferies Matthew Dellatorre - Goldman Sachs Evan Seigerman - BMO Capital Markets Geoff Meacham - Bank of America James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Gary Nachman - Raymond James Operator My name is Julianne and I'll be your conference facilitator today for Amgen's Conference Call Following The American Thoracic Society 2024 International Conference and the Approval of IMDELLTRA. All lines have been placed on mute to prevent any background noise.
05/20 13:34 EST - investorplace.com
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
05/20 07:14 EST - https://www.defenseworld.net
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
Panagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,025 shares of the medical research company’s stock after selling 899 shares during the period. Panagora Asset Management Inc.’s holdings in Amgen were worth $2,599,000 at the end of the most recent reporting period. Several other institutional investors have also made changes to their positions in AMGN. Briaud Financial Planning Inc bought a new stake in shares of Amgen during the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the fourth quarter worth approximately $29,000. Providence Capital Advisors LLC bought a new position in shares of Amgen in the third quarter valued at approximately $30,000. Planned Solutions Inc. acquired a new stake in shares of Amgen in the fourth quarter worth $30,000. Finally, Delos Wealth Advisors LLC boosted its holdings in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds. Amgen Trading Down 0.7 % Shares of AMGN opened at $312.47 on Monday. The stock’s fifty day simple moving average is $281.36 and its 200-day simple moving average is $284.31. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.62 billion, a PE ratio of 44.64, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the prior year, the company posted $3.98 EPS. The company’s revenue was up 22.0% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.46 earnings per share for the current year. Amgen Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 128.57%. Analyst Ratings Changes A number of research firms have recently issued reports on AMGN. UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Morgan Stanley raised their price target on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $305.65. Check Out Our Latest Analysis on AMGN Insider Buying and Selling at Amgen In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.69% of the company’s stock. Amgen Profile (Free Report) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Read More Five stocks we like better than Amgen Best Aerospace Stocks Investing JD’s Earnings Could Mean Chinese Stocks Making a Comeback CD Calculator: Certificate of Deposit Calculator Canada Goose Flies Higher Driven By DTC Growth 3 REITs to Buy and Hold for the Long Term CVS Health Stock Has a Silver Lining Called Value Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
Panagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,025 shares of the medical research company’s stock after selling 899 shares during the period. Panagora Asset Management Inc.’s holdings in Amgen were worth $2,599,000 at the end of the most recent reporting period. Several other institutional investors have also made changes to their positions in AMGN. Briaud Financial Planning Inc bought a new stake in shares of Amgen during the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the fourth quarter worth approximately $29,000. Providence Capital Advisors LLC bought a new position in shares of Amgen in the third quarter valued at approximately $30,000. Planned Solutions Inc. acquired a new stake in shares of Amgen in the fourth quarter worth $30,000. Finally, Delos Wealth Advisors LLC boosted its holdings in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds. Amgen Trading Down 0.7 % Shares of AMGN opened at $312.47 on Monday. The stock’s fifty day simple moving average is $281.36 and its 200-day simple moving average is $284.31. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.62 billion, a PE ratio of 44.64, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the prior year, the company posted $3.98 EPS. The company’s revenue was up 22.0% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.46 earnings per share for the current year. Amgen Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 128.57%. Analyst Ratings Changes A number of research firms have recently issued reports on AMGN. UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Morgan Stanley raised their price target on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $305.65. Check Out Our Latest Analysis on AMGN Insider Buying and Selling at Amgen In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.69% of the company’s stock. Amgen Profile (Free Report) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Read More Five stocks we like better than Amgen Best Aerospace Stocks Investing JD’s Earnings Could Mean Chinese Stocks Making a Comeback CD Calculator: Certificate of Deposit Calculator Canada Goose Flies Higher Driven By DTC Growth 3 REITs to Buy and Hold for the Long Term CVS Health Stock Has a Silver Lining Called Value Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
05/19 17:15 EST - prnewswire.com
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.
05/19 06:15 EST - fool.com
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to report positive news.
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to report positive news.
05/17 12:51 EST - zacks.com
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
05/17 11:06 EST - zacks.com
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
05/17 08:24 EST - fool.com
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.
05/16 20:21 EST - marketwatch.com
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
05/16 18:46 EST - prnewswire.com
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.
05/16 15:57 EST - cnbc.com
FDA approves Amgen's treatment for most deadly form of lung cancer
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
FDA approves Amgen's treatment for most deadly form of lung cancer
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
05/16 15:23 EST - reuters.com
US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports
The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday.
US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports
The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday.
05/16 10:29 EST - forbes.com
The Best Dividend Stocks For A Dovish Fed
Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.
The Best Dividend Stocks For A Dovish Fed
Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.
05/16 10:06 EST - zacks.com
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
05/15 18:45 EST - prnewswire.com
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.
05/15 13:03 EST - youtube.com
Trade Tracker: Joe Terranova buys Amgen and Merck
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys
Trade Tracker: Joe Terranova buys Amgen and Merck
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys
05/14 16:43 EST - seekingalpha.com
Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2024 Health Care Conference May 14, 2024 ET Company Participants Peter Griffith - EVP & CFO James Bradner - EVP, Research and Development & Chief Scientific Officer Justin Claeys - VP, IR Conference Call Participants Geoff Meacham - BofA Securities Peter Griffith [Call Starts Abruptly] for the Phase II study is complete and that we are confident in MariTide's differentiated profile and are actively planning a broad Phase 3 program, including obesity, obesity-related conditions, and diabetes. We've also initiated activities to further expand manufacturing capacity with both clinical and commercial supply in mind.
Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2024 Health Care Conference May 14, 2024 ET Company Participants Peter Griffith - EVP & CFO James Bradner - EVP, Research and Development & Chief Scientific Officer Justin Claeys - VP, IR Conference Call Participants Geoff Meacham - BofA Securities Peter Griffith [Call Starts Abruptly] for the Phase II study is complete and that we are confident in MariTide's differentiated profile and are actively planning a broad Phase 3 program, including obesity, obesity-related conditions, and diabetes. We've also initiated activities to further expand manufacturing capacity with both clinical and commercial supply in mind.
05/13 11:00 EST - investorplace.com
The 3 Best Dow Stocks to Buy in May 2024
The Dow Jones Industrial Average is on a hot streak, rising each of the first nine days of May. According to Barron's, only three of the index's 30 components — Intel (NASDAQ: INTC ), Disney (NYSE: DIS ) and McDonald's (NYSE: MCD ) — dropped in that time.
The 3 Best Dow Stocks to Buy in May 2024
The Dow Jones Industrial Average is on a hot streak, rising each of the first nine days of May. According to Barron's, only three of the index's 30 components — Intel (NASDAQ: INTC ), Disney (NYSE: DIS ) and McDonald's (NYSE: MCD ) — dropped in that time.
05/13 08:30 EST - forbes.com
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.
05/12 09:15 EST - fool.com
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine.
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine.